Is the worst over for ResMed shares?

ResMed shares have rebounded 13% since hitting a four-year low last Friday.

| More on:
A young girl dressed in socks and pyjamas smiles as she bounces in a colourful jumping castle.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ResMed Inc (ASX: RMD) shares have rebounded by 12.87% since hitting a four-year low of $21.25 last Friday.

The ResMed share price is currently $24.02, up 4.48%, making it one of the top five ASX 200 risers today.

The sleep treatment company's share price has been under pressure amid concerns that highly effective GLP-1 diabetes and obesity medicines like Ozempic could reduce demand for ResMed's medical devices.

ResMed shares also fell 10% in just one day in August when the company released its FY23 results, revealing an 18% revenue bump but an 80 basis-point fall in gross margin to 55.8%.

Overall, ResMed shares have tumbled 26% over the past six months.

But does this week's rebound indicate the worst is over?

ResMed shares rebounding as brokers say buy

Firstly, let's recap why there is concern among investors about these diabetes and obesity medicines.

Obesity is a common precursor to Type 2 diabetes and can cause obstructive sleep apnoea (OSA).

ResMed makes continuous positive airway pressure (CPAP) machines that treat sleep apnoea.

Research shows 70% of people suffering from OSA also suffer from obesity. So, investors are worried that GLP-1 medicines will remove a big chunk of the market for ResMed's CPAP machines and other devices.

But my Fool colleague Mitch points out that the OSA market opportunity for ResMed is still huge, even if you remove obese patients from the picture.

Harvard Health estimates that sleep apnoea affects an estimated 20% of the world's 8.1 billion people.

If 30% of them do not suffer from obesity, that leaves a potential market of 485 million people who are already using ResMed's products or may benefit from using them as future customers.

ResMed's total customer profile for all its products is less than half this at 160 million.

Thus, Ozempic and similar GLP-1 medicines may not disrupt ResMed's business as much as investors fear.

This is one of the reasons why Mitch bought ResMed shares for his own portfolio last week.

Here's what the experts say

Top broker Goldman Sachs makes the same point as Mitch. The broker says the OSA market "remains under-penetrated, with global estimates suggesting <20% and many countries well below this level".

Goldman is among a bunch of brokers recommending that investors buy the dip on ResMed shares.

It recently reiterated its buy rating on ResMed but reduced its 12-month price target to $33. This implies a potential upside of 37% for ASX investors who buy ResMed shares today.

Goldman has considered the impact of obesity medicines on ResMed's business and developed a base case that has informed their latest stock rating and price target.

The broker explains:

Our base scenario adopts our base case obesity forecasts from above (i.e. -7% reduction in obese or overweight with comorbidity population by 2030E). It then assumes the following patient retention on CPAP (mild 55%; moderate 70%; severe 80%). In this scenario we could see only a modest benefit of AHI [Apnea-Hyponea Index] in GPI-2 over GPI-1, which could result in a lower level of patients.

Overall, we expect continued adoption/success of the GLP-1/GIP class to reduce the OSA population addressable by CPAP, but the impact to RMD/FPH is mitigated by: i) long-term market share gains from competitors; and ii) continued improvements in OSA diagnosis rates (potentially catalysed by the GLP-1/GIP class itself).

Macquarie recently retained its outperform rating on ResMed shares with a trimmed price target of $32.60.

Wilsons retains its overweight rating and a 12-month share price target of $36.25.

Analyst Shane Storey says:

As stunning as some of the new GLP-1Ra agents look, they are unlikely to impact the gross epidemiology of OSA.

Whether they are approved or not for an OSA indication, they look unlikely to provide complete resolution of OSA symptoms and to combat CPAP as standard of care.

Bell Potter adds another point, saying, "Competitive dynamics are very much in favour of RMD due to the Philips recall and improving semiconductor availability".

The broker currently has a buy rating and a $39 price target on ResMed shares.

Morgans also has an add rating on ResMed shares with a $36.95 price target.

Motley Fool contributor Bronwyn Allen has positions in Macquarie Group. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group, Macquarie Group, and ResMed. The Motley Fool Australia has positions in and has recommended Macquarie Group and ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Portrait, confidence and team of doctors in the hospital standing after a consultation or surgery. Success, healthcare and group of professional medical workers in collaboration at a medicare clinic.
Healthcare Shares

Macquarie's top 3 ASX stock picks in the healthcare sector

Top broker has revealed 3 healthcare stocks with upside. 

Read more »

Two lab workers fist pump each other.
Healthcare Shares

3 of the best ASX 200 healthcare shares to bring your portfolio to life

These shares could be just what the investment doctor ordered according to analysts.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Share Gainers

Guess which ASX All Ords stock just rocketed 28% on a new commercial contract!

The ASX All Ords stock has grabbed plenty of investor interest on Tuesday.

Read more »

Five healthcare workers standing together and smiling.
Healthcare Shares

Is the CSL share price a buy? Here's a top broker's view

Is this stock a healthy opportunity? Let’s have a look.

Read more »

Man ecstatic after reading good news.
Healthcare Shares

Which ASX company has just secured FDA approval?

This stock just announced some big news.

Read more »

Health professional putting on gloves.
Healthcare Shares

How will Ansell shares navigate tariffs according to Macquarie?

The next two years could be a challenging period for the PPE company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is surging 18% on big news

This stock is getting a lot of love from investors on Monday.

Read more »

A man casually dressed looks to the side in a pensive, thoughtful manner with one hand under his chin, holding a mobile phone in his hand while thinking about something.
Healthcare Shares

CSL shares are having a tough time recently. Are they a buy or a sell?

Is now a good time to jump in and buy this blue chip star?

Read more »